A detailed history of Algert Global LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Algert Global LLC holds 36,986 shares of ARWR stock, worth $726,035. This represents 0.02% of its overall portfolio holdings.

Number of Shares
36,986
Previous 40,466 8.6%
Holding current value
$726,035
Previous $1.05 Million 31.94%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$19.36 - $29.54 $67,372 - $102,799
-3,480 Reduced 8.6%
36,986 $716,000
Q2 2024

Aug 14, 2024

BUY
$21.87 - $28.24 $451,746 - $583,325
20,656 Added 104.27%
40,466 $1.05 Million
Q1 2024

May 14, 2024

BUY
$27.21 - $39.48 $294,684 - $427,568
10,830 Added 120.6%
19,810 $567,000
Q4 2023

Feb 14, 2024

SELL
$21.2 - $31.03 $1.13 Million - $1.66 Million
-53,445 Reduced 85.61%
8,980 $275,000
Q3 2023

Nov 13, 2023

SELL
$26.2 - $36.08 $1.44 Million - $1.98 Million
-54,870 Reduced 46.78%
62,425 $1.68 Million
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $2.43 Million - $4 Million
96,675 Added 468.84%
117,295 $4.18 Million
Q1 2023

May 12, 2023

BUY
$23.68 - $38.51 $488,281 - $794,076
20,620 New
20,620 $524,000
Q3 2022

Nov 15, 2022

BUY
$29.63 - $48.31 $436,835 - $712,234
14,743 Added 24.28%
75,462 $2.49 Million
Q2 2022

Aug 15, 2022

BUY
$27.79 - $50.61 $737,935 - $1.34 Million
26,554 Added 77.72%
60,719 $2.14 Million
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $868,113 - $1.53 Million
21,911 Added 178.81%
34,165 $1.57 Million
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $149,407 - $212,215
-2,572 Reduced 17.35%
12,254 $812,000
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $865,541 - $1.26 Million
14,826 New
14,826 $926,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.